言語を選択
新規登録

HLA-A*0201 & B2M & EW (QLQNPSYDK)

HLA-A*0201 & B2M & EW (QLQNPSYDK) 製品リスト

  • 属性

    Protein (1)

  • 製品ライブラリ

    オンライン (1)

  • 種

    Human (1)

  • タグ

    His Tag & Avi Tag (1)

  • マーカー

    Biotin-labeled (1)

製品番号種発現システム製品説明タンパク質の構造純度特性
HLE-H82E4
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&EW (QLQNPSYDK) Complex Protein (Monomer, MALS verified)
総数量1
  • 1

HLA-A*0201 & B2M & EW (QLQNPSYDK)バックグランド

The EW peptide (QLQNPSYDK) is a Pin1-specific inhibitor derived from the CD99 protein. It functions by blocking Pin1's enzymatic activity, making it a valuable research tool for investigating Pin1-related pathways in cancer and neurodegeneration, and a prototype for therapeutic development.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
SHR-A1921SHR-A1921; SHRA1921; SHR-1921Phase 3 ClinicalSolid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung
詳細
ESG-401ESG-401; STI-3258Phase 3 ClinicalShanghai Escugen Biotechnology Co LtdOvarian Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer
詳細
OBI-992OBI-992Phase 2 ClinicalObi Pharma Usa IncSolid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung
詳細
HS-20105HS-20105; HS20105Phase 2 ClinicalHansoh BioMedical R&D CompanySolid tumours
詳細
IBI130IBI130; IBI-130Phase 2 ClinicalInnovent Biologics(Suzhou) Co LtdSolid tumours; Neoplasm Metastasis
詳細
Anti TROP2 antibody drug conjugate ADC（Fudan University）Phase 2 ClinicalFudan UniversityTriple Negative Breast Neoplasms
詳細
9MW-29219MW2921; 9MW-2921Phase 2 ClinicalMabwell (Shanghai) Bioscience Co LtdSolid tumours
詳細
MHB036CMHB-036CPhase 2 ClinicalMinghui Pharmaceutical Pty LtdSolid tumours; Lung Neoplasms
詳細
BAT-8008BAT-8008; BAT8008Phase 2 ClinicalBio-Thera Solutions LtdSolid tumours; Triple Negative Breast Neoplasms
詳細
DB-1305DB1305; BNT325; DB-1305; BNT-325Phase 2 ClinicalSolid tumours
詳細
BIO-106BIO-106Phase 2 ClinicalHangzhou Baikai Biopharmaceutical Co LtdSolid tumours; Neoplasms
詳細
BL-M02D1Phase 2 ClinicalBaili-Bio (Chengdu) Pharmaceutical Co LtdSolid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung
詳細
LCB-84LCB-84Phase 2 ClinicalLegochem Biosciences IncSolid tumours
詳細
FDA018 Antibody Drug ConjugateFDA018-ADC; FDA-018-ADCPhase 2 ClinicalShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdSolid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Neoplasm Metastasis
詳細
DAC-002DAC-002; JS-108Phase 1 ClinicalHangzhou Dac Biotech Company LtdSolid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma
詳細
JSKN-016JSKN016; JSKN-016Phase 1 ClinicalJiangsu Alphamab Biopharmaceuticals Co LtdSolid tumours; Neoplasms
詳細
DXC-1002DXC1002; DXC-1002Phase 1 ClinicalHangzhou Dac Biotech Company LtdSolid tumours
詳細
FZ-AD004FZ-AD004Phase 1 ClinicalShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdSolid tumours
詳細
MT-302MT-302Phase 1 ClinicalMyeloid Therapeutics IncCarcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Sacituzumab govitecanIMMU-132; TROP-2-SN-38; IMMU0132; GS-0132; IMMU-0132ApprovedTrodelvy, 拓达维, TRODELVYUnited StatesTriple Negative Breast NeoplasmsImmunomedics Inc2020-04-22Mesothelioma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Thymoma; Brain metastases; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Metastatic breast cancer; Bile Duct Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Klatskin Tumor; Urinary Bladder Neoplasms; Liver Failure; Thyroid Carcinoma, Anaplastic; Salivary Gland Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Solid tumours
詳細
Sacituzumab tirumotecanSKB-264; MK-2870; SKB264; sac-TMTApprovedKlus Pharma Inc佳泰莱Mainland ChinaTriple Negative Breast NeoplasmsSichuan Kelun-Biotech Biopharmaceutical Co Ltd2024-11-22Triple Negative Breast Neoplasms; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours
詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報
共有：

採用情報法的規制サイトマッププライバシーポリシー利用規約
ウェブサイトに関するフィードバック
お問い合わせ

お問い合わせ
グローバル：+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8